Generics manufacturers increase investment in injectables

Home/Pharma News | Posted 30/08/2013 post-comment0 Post your comment

Generic drugmaker Zydus Cadila, the fifth largest pharmaceutical company in India, is set to invest about US$15.8 million in building an FDA-approved injectables-manufacturing plant. The news in August 2013 came just as Aurobindo Pharma announced plans to spin-off its injectables business to strengthen that side of its operations further.

picture 116

Zydus Cadila’s new manufacturing plant will be based in Vadodara, not far from its base in Ahmedabad. The company’s first focus will be on the US market, to be followed by Brazil and Europe. Aurobindo Pharma has plans to nearly quadruple sterile injectable capacity at a plant near Hyderabad.

The US market for injectables has been attracting widespread attention from the pharmaceutical industry. The number of drug shortages in the US has tripled in the last six years, and most have been the result of shortages in generic sterile injectables [1]. The injectable drug delivery market in the US has been predicted to grow to US$43.3 billion by 2017.

Medical technology company Becton Dickinson announced in March 2013 that FDA had approved the first drug in its line of pre-filled generic injectables (diphenhydramine hydrochloride, an antihistamine) [1]. The company has been investing heavily in its new manufacturing facility to produce these generic injectables.

All this comes in the wake of generics giant Mylan announcing in February 2013 that it had signed an agreement to acquire generic injectables maker Agila Specialties (Agila) from Strides Arcolab for US$1.6 billion [2]. According to IMS, the global generic injectables market is expected to grow at a compound annual growth rate of 13% from 2011–2017 driven by patent expiries.


1.  GaBI Online - Generics and Biosimilars Initiative. New entrant to generic injectables market []. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Aug 30]. Available from:

2.  GaBI Online - Generics and Biosimilars Initiative. Mylan to acquire Strides Arcolab’s injectable generics business []. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Aug 30]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010